Market news
Takeda Pharmaceutical (TSE:4502) agreed a multi-year collaboration with the Indonesian Government to develop the country's plasma collection and biopharmaceutical manufacturing ecosystem. The company also reported Phase 3 data for its TYK2 inhibitor zasocitinib in plaque psoriasis, with trial results showing consistent and high skin clearance rates in difficult to treat patients. For investors following large global drug companies, Takeda Pharmaceutical sits at the intersection of specialty...
Thalia Therapeutics (LSE:THAT) is strengthening its position in the RNA therapeutics sector through the proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2. 75 million fundraising, supporting its transition into a clinical-stage biotechnology company.
This is the newest page. Registered accounts read further back.